MOR
MorphoSys AG
7.08
USD
This page is just a preview of the data found in TrendSpider’s full version
MorphoSys AG stock is down -9.69% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 3 CALLs, 7 PUTs. 67% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 20 Nov 18:07 | 19 Jan, 2024 | 10.00 | 17344 | ||
| 20 Nov 20:51 | 19 Jan, 2024 | 10.00 | 17344 | ||
| 20 Nov 20:56 | 19 Jan, 2024 | 10.00 | 17344 | ||
| 21 Nov 17:54 | 19 Jan, 2024 | 5.00 | 393 | ||
| 22 Nov 15:42 | 19 Jan, 2024 | 5.00 | 969 | ||
| 24 Nov 14:42 | 19 Jan, 2024 | 5.00 | 1210 | ||
| 24 Nov 15:48 | 19 Apr, 2024 | 5.00 | 40 | ||
| 24 Nov 16:14 | 19 Apr, 2024 | 7.50 | 441 | ||
| 30 Nov 15:00 | 19 Apr, 2024 | 7.50 | 652 | ||
| 07 Dec 15:36 | 19 Jan, 2024 | 7.50 | 1538 |
MorphoSys AG engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis.
